Luedeman, Megan E. http://orcid.org/0000-0003-3616-0770
Stroik, Susanna
Feng, Wanjuan
Luthman, Adam J.
Gupta, Gaorav P. http://orcid.org/0000-0001-9177-552X
Ramsden, Dale A. http://orcid.org/0000-0003-1575-4748
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5T32 GM007092, T32 GM119999)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32CA264891, P01CA247773, P01CA247773)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Defense (W81XWH18-1-0046)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 2 February 2022
Accepted: 18 July 2022
First Online: 4 August 2022
Competing interests
: G.P.G. receives research funding from Breakpoint Therapeutics, which is developing inhibitors of Polθ. D.A.R. has a materials transfer agreement with Artios Pharma and is using an Artios Pharma compound that inhibits Polθ for research purposes with no financial compensation. M.L. accepted employment at Promega Corporation, manufacturer of the Halo-tag and ligand. The remaining authors declare no competing interests.